Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms IXORA-P
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 23 Sep 2019 Results assessing indirect comparison of long-term efficacy of every-two week versus recommended dosing of ixekizumab by using data from four studies (IXORA P, UNCOVER 1, 2 and 3) published in the British Journal of Dermatology.
    • 10 Sep 2018 According to an Eli Lilly media release, data from this trial will be presented at the 27th annual European Academy of Dermatology and Venereology (EADV) Congress (Sep 2018).
    • 06 Feb 2018 Primary endpoint has been met. (Proportion of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75) in Q2W dose group versus the Q4W dose group) as per results published in British Journal of Dermatology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top